Zong Sheng Guo

List of Publications by Year
in descending order

97 papers	5,954 citations	87888 38 h-index	79698 73 g-index
97 all docs	97 docs citations	97 times ranked	7257 citing authors

#	Article	IF	Citations
1	Intrapleural interleukin-2â€“expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e313-e328.	0.8	13
2	Immunogenic cell deathâ€inducing small molecule inhibitors: Potential for immunotherapy of cancer. Clinical and Translational Discovery, 2022, 2, .	0.5	1
3	Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy. Biomedicines, 2022, 10, 1425.	3.2	11
4	Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Therapy, 2021, 28, 98-111.	4.6	30
5	In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Frontiers in Immunology, 2021, 12, 610042.	4.8	6
6	IL-36Î³-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. Cancer Immunology, Immunotherapy, 2021, 70, 2467-2481.	4.2	13
7	Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Annals of Surgical Oncology, 2021, 28, 2715-2727.	1.5	11
8	Oncolytic Virus Immunotherapy: Showcasing Impressive Progress in Special Issue II. Biomedicines, 2021, 9, 663.	3.2	4
9	PDLIM2: Signaling pathways and functions in cancer suppression and host immunity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188630.	7.4	13
10	Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Theranostics, 2021, 11, 6668-6681.	10.0	22
11	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular Cancer, 2021, 20, 171.	19.2	106
12	Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 2020, 8, 204.	3.2	41
13	Oncolytic immunotherapy for metastatic cancer: lessons and future strategies. Annals of Translational Medicine, 2020, 8, 1113-1113.	1.7	3
14	In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Molecular Therapy - Oncolytics, 2020, 17, 350-360.	4.4	23
15	Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. , 2020, 8, e000294.		37
16	Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical Cancer Research, 2020, 26, 2216-2230.	7.0	39
17	Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. , 2020, 8, e000710.		43
18	Abstract 912: Synergistic combination of oncolytic virotherapy and immunotherapy for glioma. , 2020, , .		0

#	Article	IF	Citations
19	A cautionary note on the selectivity of oncolytic poxviruses . Oncolytic Virotherapy, 2019, Volume 8, 3-8.	6.0	14
20	Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. , 2019, 7, 6.		190
21	Abstract 2264: Synergistic combination of oncolytic virotherapy and immunotherapy for glioma. , 2019, , .		0
22	Abstract 2264: Synergistic combination of oncolytic virotherapy and immunotherapy for glioma. , 2019, , .		0
23	Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nature Communications, 2018, 9, 4682.	12.8	59
24	The 2018 Nobel Prize in medicine goes to cancer immunotherapy. BMC Cancer, 2018, 18, 1086.	2.6	54
25	Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Molecular Therapy, 2018, 26, 2476-2486.	8.2	107
26	PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5. Autophagy, 2018, 14, 1870-1885.	9.1	23
27	Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications, 2017, 8, 14754.	12.8	268
28	Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Molecular Therapy - Methods and Clinical Development, 2017, 7, 112-122.	4.1	10
29	The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells. Cancer Immunology Research, 2017, 5, 908-919.	3.4	25
30	Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer. Biomedicines, 2017, 5, 52.	3.2	5
31	Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Frontiers in Immunology, 2017, 8, 555.	4.8	76
32	Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. Oncotarget, 2017, 8, 106888-106900.	1.8	19
33	Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Molecular Therapy, 2016, 24, 1492-1501.	8.2	110
34	TRAILâ€Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stressâ€Induced Signal Transduction Pathways. Journal of Cellular Biochemistry, 2016, 117, 1078-1091.	2.6	11
35	CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. OncoImmunology, 2016, 5, e1091554.	4.6	83
36	Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors. Translational Research, 2016, 169, 19-30.e1.	5.0	25

#	Article	IF	Citations
37	Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer. Annals of Surgical Oncology, 2016, 23, 655-662.	1.5	27
38	Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer. Oncotarget, 2016, 7, 22174-22185.	1.8	37
39	Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Molecular Therapy - Oncolytics, 2015, 2, 15011.	4.4	42
40	Oncolysis by paramyxoviruses: preclinical and clinical studies. Molecular Therapy - Oncolytics, 2015, 2, 15017.	4.4	33
41	Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth. Translational Research, 2015, 166, 344-354.	5.0	27
42	First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity. Molecular Therapy, 2015, 23, 202-214.	8.2	117
43	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
44	Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Frontiers in Oncology, 2014, 4, 74.	2.8	216
45	Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Therapy, 2014, 21, 261-263.	4.6	22
46	Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology, 2014, 59, 1448-1458.	7.3	37
47	T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy. Molecular Therapy, 2014, 22, 102-111.	8.2	140
48	Oncolytic viruses as therapeutic cancer vaccines. Molecular Cancer, 2013, 12, 103.	19.2	252
49	A Rationally Designed A34R Mutant Oncolytic Poxvirus: Improved Efficacy in Peritoneal Carcinomatosis. Molecular Therapy, 2013, 21, 1024-1033.	8.2	25
50	Inhibitors of C5 complement enhance vaccinia virus oncolysis. Cancer Gene Therapy, 2013, 20, 342-350.	4.6	24
51	Local Administration of TLR Ligands Rescues the Function of Tumor-Infiltrating CD8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization. Journal of Immunology, 2013, 190, 5866-5873.	0.8	24
52	miR-574-5p negatively regulates<i>Qki6/7</i>to impact<i>Î²-catenin</i>/Wnt signalling and the development of colorectal cancer. Gut, 2013, 62, 716-726.	12.1	112
53	Life after death: targeting high mobility group box 1 in emergent cancer therapies. American Journal of Cancer Research, 2013, 3, 1-20.	1.4	50
54	Oncolytic Virus and Antiâ€“4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer. Cancer Research, 2012, 72, 1651-1660.	0.9	94

#	Article	IF	Citations
55	Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Therapy, 2012, 19, 192-201.	4.6	8
56	Mucin as a therapeutic target in pseudomyxoma peritonei. Journal of Surgical Oncology, 2012, 106, 911-917.	1.7	31
57	Chronic Anti-inflammatory Drug Therapy Inhibits Gel-Forming Mucin Production in a Murine Xenograft Model of Human Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2012, 19, 1402-1409.	1.5	26
58	Abstract 5253: MEK-ERK pathway inhibition reduces mucin production in a murine xenograft model of pseudomyxoma peritonei. , 2012, , .		0
59	Abstract 1544: Combined oncolytic virotherapy and immunotherapy for malignant mesothelioma. , 2012, , .		0
60	Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. Molecular Cancer, 2011, 10, 63.	19.2	13
61	CXCL11 improves safety of oncolytic vaccinia virus therapy. Journal of the American College of Surgeons, 2011, 213, S138.	0.5	0
62	Aldo-keto reductase-7A protects liver cells and tissues from acetaminophen-induced oxidative stress and hepatotoxicity. Hepatology, 2011, 54, 1322-1332.	7.3	47
63	Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Molecular Therapy, 2011, 19, 650-657.	8.2	119
64	Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality CD8 Memory T Cells and Prevent Autochthonous Mouse Melanoma. Journal of Immunology, 2011, 187, 1788-1796.	0.8	16
65	The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Therapy, 2010, 17, 1465-1475.	4.5	46
66	TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Therapy, 2010, 17, 550-559.	4.5	32
67	Epigenetic drugs for cancer treatment and prevention: mechanisms of action. Biomolecular Concepts, 2010, 1, 239-251.	2.2	15
68	Three Epigenetic Drugs Up-Regulate Homeobox GeneRhox5in Cancer Cells through Overlapping and Distinct Molecular Mechanisms. Molecular Pharmacology, 2009, 76, 1072-1081.	2.3	35
69	JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase. Cancer Gene Therapy, 2008, 15, 616-624.	4.6	21
70	Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Therapy, 2008, 15, 115-125.	4.6	65
71	Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 217-231.	7.4	111
72	Quercetin augments TRAIL-induced apoptotic death: Involvement of the ERK signal transduction pathway. Biochemical Pharmacology, 2008, 75, 1946-1958.	4.4	156

#	Article	IF	Citations
73	Gene transfer: the challenge of regulated gene expression. Trends in Molecular Medicine, 2008, 14, 410-418.	6.7	55
74	Aldose Reductase Regulates Hepatic Peroxisome Proliferator-activated Receptor Î± Phosphorylation and Activity to Impact Lipid Homeostasis. Journal of Biological Chemistry, 2008, 283, 17175-17183.	3.4	46
75	Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy. Cancer Biology and Therapy, 2007, 6, 1773-1779.	3.4	19
76	5-AZA-2â€²-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. Cancer Research, 2007, 67, 2901-2901.	0.9	0
77	A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Therapy, 2007, 14, 638-647.	4.5	25
78	De novo Induction of a Cancer/Testis Antigen by 5-Aza-2â€²-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model. Cancer Research, 2006, 66, 1105-1113.	0.9	133
79	High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists. Journal of Immunology, 2006, 177, 8701-8707.	0.8	59
80	Intravenous and Isolated Limb Perfusion Delivery of Wild Type and a Tumor-Selective Replicating Mutant Vaccinia Virus in Nonhuman Primates. Human Gene Therapy, 2006, 17, 31-45.	2.7	33
81	772. Inhibition of Ovarian Tumor Growth Following Treatment with an Oncolytic Vaccinia Virus. Molecular Therapy, 2006, 13, S298-S299.	8.2	0
82	Sequential 5-Aza 2â€²-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene, 2005, 24, 2386-2397.	5.9	44
83	The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Research, 2005, 65, 9991-9998.	0.9	111
84	Vaccinia as a vector for gene delivery. Expert Opinion on Biological Therapy, 2004, 4, 901-917.	3.1	60
85	DNA Methylation May Restrict but Does Not Determine Differential Gene Expression at the Sgy/Tead2 Locus during Mouse Development. Molecular and Cellular Biology, 2004, 24, 1968-1982.	2.3	42
86	An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology, 2003, 37, 155-163.	7.3	34
87	Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228. Journal of the National Cancer Institute, 2002, 94, 504-513.	6.3	330
88	Tumor-specific transcriptional targeting of suicide gene therapy. Gene Therapy, 2002, 9, 168-175.	4.5	121
89	Induction of MAGE-3 expression in lung and esophageal cancer cells. Annals of Thoracic Surgery, 2001, 71, 295-302.	1.3	76
90	Sequential 5-Aza-2â€™-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1. Journal of Immunotherapy, 2001, 24, 151-161.	2.4	162

#	Article	IF	Citations
91	Augmenting Transgene Expression from Carcinoembryonic Antigen (CEA) Promoter via a GAL4 Gene Regulatory System. Molecular Therapy, 2001, 3, 278-283.	8.2	44
92	The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nature Medicine, 2000, 6, 826-831.	30.7	165
93	Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication.. Molecular and Cellular Biology, 1992, 12, 2514-2524.	2.3	131
94	T-antigen binding to site I facilities initiation of SV40 DNA replication but does not affect bidirectionality. Nucleic Acids Research, 1991, 19, 7081-7088.	14.5	16
95	Is c-myc protein directly involved in DNA replication?. Science, 1988, 240, 1202-1203.	12.6	27
96	Initiation of simian virus 40 DNA replicationin vitro:identification of RNA-Primed nascent DNA chains. Nucleic Acids Research, 1987, 15, 7877-7888.	14.5	14
97	The impact of hypoxia on oncolytic virotherapy. Virus Adaptation and Treatment, 0, , 71.	1.5	6